Afamelanotide is a synthetic 13-amino-acid analog of alpha-MSH, the hormone that tells skin cells to make pigment. Sold as Scenesse, it is FDA-approved for adults with erythropoietic protoporphyria (EPP), a rare disorder of painful light sensitivity. This guide covers its structure, action, label, trials and status. Every source was checked on November 17, 2026.
Quick answer: Afamelanotide is a prescription drug for one rare condition, EPP, in adults. It raises dark skin pigment without sunlight. It is not the same compound as melanotan II. The FDA label approves no other use.
Vitrapep does not sell afamelanotide; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is afamelanotide?
Afamelanotide is a peptide of 13 amino acids. The Scenesse label calls it “a synthetic tridecapeptide and a structural analog of α-melanocyte stimulating hormone (α-MSH)” (Scenesse label, 2024). PubChem gives its sequence as Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (PubChem CID 16197727).
In plain terms, it is alpha-MSH with two swaps. Norleucine replaces the amino acid at position 4, and a mirror-image phenylalanine sits at position 7. PubChem lists synonyms that reflect this, including [Nle4, D-Phe7]-α-MSH, NDP-MSH, melanotan I and CUV1647. It gives the formula C78H111N21O19 and a molecular weight of 1646.8 g/mol.
Early human research tested it as a tanning agent. A 1991 placebo-controlled human trial in 28 healthy white men reported skin darkening with the peptide and none with placebo (Levine et al., 1991). Clinuvel later developed it for EPP.
Afamelanotide: key facts
| Fact | Detail |
|---|---|
| Structure | Peptide of 13 amino acids; alpha-MSH analog with norleucine at position 4 and D-phenylalanine at position 7 |
| Class | Melanocortin receptor agonist (mainly MC1 receptor) |
| Molecular formula | C78H111N21O19 |
| Molecular weight | 1646.8 g/mol (PubChem) |
| First FDA approval | October 8, 2019 (NDA 210797) |
| Brand names | Scenesse (Clinuvel) |
How does afamelanotide work?
The label states that afamelanotide “is a melanocortin receptor agonist and binds predominantly to MC1-R.” MC1 receptors sit on melanocytes, the skin’s pigment cells. Activating them raises eumelanin, the dark form of melanin.
The label adds that afamelanotide “increases production of eumelanin in the skin independently of exposure to sunlight or artificial UV light sources.” In EPP, light exposure causes painful skin reactions. The NEJM trial report describes EPP as a severe photodermatosis with acute phototoxicity.
Setmelanotide, covered in our setmelanotide guide, works on a different member of the same receptor family, MC4. Our PT-141 guide and KPV mechanism page cover other melanocortin peptides.
What is afamelanotide approved for?
The Scenesse label, revised in August 2024, has one indication. Scenesse “is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).”
Drugs@FDA lists the original approval on October 8, 2019, as a new molecular entity with priority review and orphan status (Drugs@FDA, NDA 210797). It shows one later supplement, a labeling change on August 12, 2024. We found no FDA approval for any other condition or for patients under 18.
What did the key trials show?
Two randomized, double-blind, placebo-controlled trials in people with EPP supported approval (Langendonk et al., 2015). One ran in the European Union and one in the United States. Together they enrolled 168 patients. The primary endpoint was hours of direct sunlight exposure without pain. These are human data.
- U.S. trial (NCT01605136, 94 patients): over six months, median pain-free time was 69.4 hours with afamelanotide and 40.8 hours with placebo (P=0.04).
- EU trial (NCT00979745, 74 patients): over nine months, the medians were 6.0 and 0.8 hours (P=0.005). Phototoxic reactions were fewer with afamelanotide, 77 versus 146 (P=0.04).
Quality of life improved in both trials. The FDA label reports its own medians for the same trials: 64.1 versus 40.5 hours, and 6.0 versus 0.75 hours.
Outside EPP, a randomized trial tested afamelanotide added to narrowband UV-B light in 55 adults with vitiligo (Lim et al., 2015; NCT01430195). By day 168, repigmentation was 48.64% with the combination and 33.26% with light alone. Vitiligo is not an approved use.
What side effects does the label list?
The Scenesse label has no boxed warning. Its safety data come from 244 adults with EPP: 125 received Scenesse and 119 received a vehicle comparator. Reactions above 2% included:
- implant site reaction (21% versus 10%);
- nausea (19% versus 14%);
- oropharyngeal pain (7% versus 5%);
- cough and fatigue (6% each versus 3%);
- skin hyperpigmentation (4% versus 0%);
- dizziness, melanocytic nevus and respiratory tract infection (4% each).
Two warnings stand out. Serious hypersensitivity reactions, including anaphylaxis, have been reported. Afamelanotide may also darken existing moles and freckles. The label recommends “a full body skin examination (twice yearly)” to monitor pigmented lesions.
What is afamelanotide’s regulatory status, and is it used in research?
Prescription drug. Scenesse is an FDA-approved prescription drug for adults with EPP. Its label approves no cosmetic or tanning use.
Not melanotan II. PubChem lists “melanotan I” as a synonym for afamelanotide. Melanotan II is a different peptide. FDA’s list of bulk substances that may present significant safety risks names melanotan II in its withdrawn-nominations section (FDA, 2026). FDA’s notes cite “published case reports” of serious adverse events, including melanoma. Afamelanotide is not on that list.
Sport. WADA’s 2026 Prohibited List does not name afamelanotide. Athletes should check with their anti-doping organization. See our guide to peptides on the 2026 WADA list.
Research. ClinicalTrials.gov lists 23 studies with afamelanotide as an intervention. Conditions include vitiligo, polymorphic light eruption, xeroderma pigmentosum, variegate porphyria and stroke. A phase 3 vitiligo trial, NCT06109649, is listed as active, not recruiting. A 2026 exploratory study in nine healthy adults found a smaller skin redness response to UV light (Griffin et al., 2026). Several of its authors disclosed ties to Clinuvel. For labeling terms, see what research use only means and our overview of peptide hormones.
Frequently asked questions about afamelanotide
Is afamelanotide the same as melanotan II?
No. PubChem lists afamelanotide as melanotan I. Melanotan II is a different peptide, and FDA notes published reports of serious adverse events with it.
Is afamelanotide approved for tanning?
No. Its only FDA-approved use is to increase pain-free light exposure in adults with EPP and a history of phototoxic reactions.
Does afamelanotide need sunlight to work?
No. The label says it raises eumelanin in the skin independently of sunlight or artificial UV light.
Is afamelanotide approved for children?
Not in the United States. The current label covers adult patients only.
Is afamelanotide banned by WADA?
The 2026 list does not name it. Athletes should confirm with their anti-doping organization.
What to know now
- What it is: a 13-amino-acid analog of alpha-MSH that acts mainly on MC1 receptors.
- Approval: Scenesse, approved October 8, 2019, for adults with EPP.
- Key trials: more pain-free sunlight hours than placebo in two EPP trials.
- Side effects: local site reactions, nausea, skin darkening and others; no boxed warning.
- Identity: listed as melanotan I; not the same as melanotan II.
- Research: studied in vitiligo and other light-related conditions; none approved.
What we’re watching
Results from the phase 3 vitiligo trial NCT06109649. Any FDA label change for Scenesse on age or new conditions. And WADA’s 2027 Prohibited List, which takes effect on January 1, 2027.